Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Tamer E. Fandy, James G. Herman, Patrick Kerns, Anchalee Jiemjit, Elizabeth A. Sugar, Si Ho Choi, Allen S. Yang, Timothy Aucott, Tianna Dauses, Rosalie Odchimar-Reissig, Jonathan Licht, Melanie J. McConnell, Chris Nasrallah, Marianne K.H. Kim, Weijia Zhang, Yezou Sun, Anthony Murgo, Igor Espinoza-Delgado, Katharine Oteiza, Ibitayo OwoeyeLewis R. Silverman, Steven D. Gore, Hetty E. Carraway

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds